Figures & data
Table 1. Study inclusion criteria applied when screening articles and abstracting data.
Figure 1. Flow diagram depicting the literature review process and studies identified. HTA, health technology assessment.
![Figure 1. Flow diagram depicting the literature review process and studies identified. HTA, health technology assessment.](/cms/asset/c3844a86-d061-4a6c-a023-262c5b30183d/ijme_a_1336449_f0001_b.jpg)
Table 2. Results: frequency of statistically significant mortality data utilized within cost effectiveness analyses of lipid-lowering therapies.
Figure 2. Results: source of mortality data and use of composite and individual end-points within CEA that incorporated a direct effect.
![Figure 2. Results: source of mortality data and use of composite and individual end-points within CEA that incorporated a direct effect.](/cms/asset/cbd038a1-d0da-4f00-a90e-178d1365b56f/ijme_a_1336449_f0002_c.jpg)
Table 3. Results: quantitative assessment of mortality data sources and format of data used among studies modeling a direct mortality effect.
Table 4. Sensitivity analysis of studies that incorporated a direct CVD mortality benefit.